Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207244 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 992
- Enrollment target
NCT02207244: Completed Phase 3 study, sponsored by Janssen Research & Development.
NCT02207244 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 992 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207244, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 992 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
Primary Outcome
The IGA documents the investigator's assessment of the participants' psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Interventions
- DRUG Adalimumab
- DRUG Placebo for guselkumab
- DRUG Placebo for adalimumab
- DRUG Guselkumab 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 992 participants |
| Start Date | 2014-11-03 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 3 |
What the finished NCT02207244 record still lists
NCT02207244 is an interventional study that assigns participants to a tested intervention. The registered 992 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 4 interventions - of which Adalimumab is the first listed.
NCT02207244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02207244 about?
NCT02207244 is a clinical study titled "A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment". The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
What is the current status of trial NCT02207244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 992 participants. The study started on 2014-11-03. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT02207244?
The interventions under investigation include: Adalimumab (DRUG), Placebo for guselkumab (DRUG), Placebo for adalimumab (DRUG), Guselkumab 100 mg (DRUG).
Who is sponsoring clinical trial NCT02207244?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02207244's enrollment target sits among peer trials
992 314th of 2000 higher than 1,686 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- NCT05437575 · 994 participants · Phase 3
Prehospital Analgesia INtervention Trial (PAIN)
- NCT06671704 · 994 participants · NA
GC-PRO Intervention
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI